明樑控股(08152.HK)年度虧損大幅收窄73.06%至133.4萬港元
格隆匯3月31日丨明樑控股(08152.HK)發佈,截至2019年12月31日止12個月,公司實現收入1.41億港元,同比增長23.92%;毛利4023.1萬港元,同比增長20.94%;公司權益持有人應占期內虧損133.4萬港元,同比收窄73.06%;基本每股虧損0.22港仙;不派息。
收益增加主要由於就隧道分部確認的收入為1.313億港元,同比增長39.2%;地基分部錄得的收入為990萬港元.,同比減少49.5%。就客户地理位置而言,自香港客户所得的收入1220萬港元,而自中國以及新加坡及其他亞太國家客户所得的收入分別為約7690萬港元及2320萬港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.